Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
The study shows that early ctDNA dynamics can provide valuable insights into treatment efficacy and potential molecular relapse in 1L ES-SCLC. ctDNA can enhance treatment monitoring and potentially guide the discontinuation of ineffective therapies. Larger studies with extended next-generation sequencing panels are needed to fully understand the potential of ctDNA in SCLC management from diagnosis to treatment and recurrence surveillance.
Authors
- Silvija Kraljevic (ORCID: https://orcid.org/0000-0002-6220-7168)
- Carmela Ciardullo (ORCID: https://orcid.org/0000-0002-0809-2136)
- Lauren A. Byers (ORCID: https://orcid.org/0000-0002-0780-2677)
- T. Hedley Carr (ORCID: https://orcid.org/0000-0002-8147-9855)
- Luis Tobalina (ORCID: https://orcid.org/0000-0002-1947-8309)
- Philip Szekeres (ORCID: https://orcid.org/0009-0009-7763-4718)
- Giulia Fabbri (ORCID: https://orcid.org/0000-0003-0709-2748)
Institutions
- AstraZeneca (United Kingdom) (GB)
- The University of Texas MD Anderson Cancer Center (US)
- Massachusetts Medical Society (US)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2011
- Citations
- 3
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.14